Loading…
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Dose JPI-289, A Novel Poly (ADP-Ribose) Polymerase-1 Inhibitor in First-In-Human Study of Healthy Volunteers
Background JPI-289 is a promising poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor with therapeutic potential for acute ischemic stroke by suppressing microglial activation and facilitating neuroprotection. The plasma and urine concentrations of JPI-289 and its metabolites were determined using a v...
Saved in:
Published in: | Clinical therapeutics 2017-08, Vol.39 (8), p.e48-e48 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background JPI-289 is a promising poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor with therapeutic potential for acute ischemic stroke by suppressing microglial activation and facilitating neuroprotection. The plasma and urine concentrations of JPI-289 and its metabolites were determined using a validated liquid chromatography-mass spectrometry method. |
---|---|
ISSN: | 0149-2918 1879-114X |
DOI: | 10.1016/j.clinthera.2017.05.148 |